Paul Bunn, MD, University of Colorado Cancer Center, Aurora, CO, comments on which groups of patients with non-small cell lung cancer (NSCLC) should receive immunotherapy based their driver mutations. Whilst EGFR-mutant lung cancer will respond poorly to immunotherapy, it remains unclear whether patients with KRAS or BRAF mutations will benefit from immunotherapy before or after receiving tyrosine kinase inhibitors (TKIs) such as sotorasib, dabrafenib, and trametinib. For patients who progress from TKIs, additional questions remain over whether they should receive chemotherapy alone or with immunotherapy, with the results from the Phase III IMpower150 (NCT02366143) suggesting the latter. This interview took place at the 7th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting (PRIMO 2022).